Nusano has entered an agreement to supply multiple medical isotopes to Taiwan-based radiopharmaceutical developer Primo Biotechnology to support the company's Primo’s cancer therapy pipeline.
Under the agreement, Primo will gain access to the following isotopes:
Lutetium-177
Actinium-225
Indium-111
Zirconium-89
Terbium-161
Nusano’s production platform combines technologies from universities and research centers with the company’s patented particle acceleration technology. The platform can manufacture up to 12 radioisotopes at the same time, according to the firm.
Primo is developing drugs through its Primo-X platform, which covers drug research and development, clinical translation, and manufacturing, the company said.
